The non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market size has grown exponentially in recent years. It will grow from $3.68 billion in 2025 to $4.82 billion in 2026 at a compound annual growth rate (CAGR) of 31.2%. The growth in the historic period can be attributed to dominance of peptide-based GLP-1 injectable therapies, rising global prevalence of type 2 diabetes and obesity, limited oral bioavailability of early GLP-1 compounds, high cost and long development timelines of peptide drugs, and regulatory approvals of first-generation GLP-1 receptor agonists.
The non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market size is expected to see exponential growth in the next few years. It will grow to $14.39 billion in 2030 at a compound annual growth rate (CAGR) of 31.4%. The growth in the forecast period can be attributed to the expansion of oral small molecule GLP-1 agonist development pipelines, widening applications of multi-indication metabolic therapies, rising innovation in non-peptide receptor modulation technologies, increasing strategic collaborations and licensing agreements among pharmaceutical and biotechnology companies, and a growing shift toward personalized approaches in metabolic disease management. Major trends in the forecast period include the expansion of oral non-peptide GLP-1 receptor agonist development, increasing growth of multi-indication metabolic therapeutics targeting obesity and diabetes, rising adoption of combination metabolic therapies for improved efficacy, advancements in small molecule drug discovery focused on GLP-1 pathway modulation, and development of next-generation oral bioavailability enhancement technologies for peptide-free metabolic drugs.
The rising prevalence of obesity is expected to drive the expansion of the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market in the future. Obesity is a medical condition characterized by excessive accumulation of body fat that can adversely affect health and increase the risk of diseases such as diabetes, cardiovascular disease, and hypertension. The increasing prevalence of obesity is primarily driven by unhealthy dietary patterns, including high consumption of calorie-dense, processed, and sugary foods, combined with low levels of physical activity. The non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline addresses obesity by enabling orally available GLP-1 receptor agonists that regulate appetite, enhance satiety, and improve metabolic function, thereby promoting sustained weight reduction. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, approximately 64.5% of adults aged 18 and over in England were classified as overweight or living with obesity, compared to 64% in 2022 to 2023. Therefore, the increasing prevalence of obesity is driving the growth of the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market.
Key companies operating in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market are focusing on conducting clinical trials to develop innovative products such as oral small-molecule GLP-1 receptor agonists to improve patient convenience, enhance metabolic disease management, and expand treatment options beyond injectable therapies. Oral small-molecule GLP-1 receptor agonists refer to chemically synthesized non-peptide compounds designed to mimic the activity of natural GLP-1 hormones by binding to and activating GLP-1 receptors, helping regulate blood glucose levels, suppress appetite, and support weight loss without requiring peptide-based injections. For example, in April 2026, Structure Therapeutics Inc., a US-based pharmaceutical company, announced that the first patients had been dosed in the Phase 2b ACCESS clinical study evaluating its oral small-molecule GLP-1 receptor agonist GSBR-1290 for the treatment of obesity. The study is designed to evaluate the safety, tolerability, and efficacy of the therapy in individuals with obesity, with a focus on its potential to support clinically meaningful weight reduction and improved metabolic outcomes. GSBR-1290 represents an oral, non-peptide alternative to injectable GLP-1 therapies, aiming to improve patient convenience and long-term treatment adherence.
In January 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical and diagnostics company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, F. Hoffmann-La Roche Ltd. aims to strengthen its obesity and diabetes pipeline by gaining access to Carmot Therapeutics Inc.’s portfolio of metabolic disease therapies, including CT-996, an oral non-peptide small-molecule GLP-1 receptor agonist, along with additional GLP-1 and GIP-targeting assets for obesity and type 2 diabetes treatment. Carmot Therapeutics Inc. is a US-based clinical-stage biotechnology company developing a non-peptide small-molecule GLP-1 receptor agonist-based pipeline for metabolic diseases.
Major companies operating in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market are Eli Lilly and Company, AstraZeneca PLC, Novo Nordisk A/S, Amgen, Viking Therapeutics Inc., Structure Therapeutics Inc., Metsera, Sciwind Biosciences Co. Ltd., Boehringer Ingelheim International GmbH, Roche Holding AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Zealand Pharma A/S, Hansoh Pharmaceutical Group Company Limited, Jiangsu Hengrui Pharmaceuticals Co Ltd., Septerna Inc., Eccogene Inc., Corxel Pharmaceuticals Limited, Gan And Lee Pharmaceuticals Co Ltd., Ascletis Pharma Inc., PegBio Co.Ltd., Regor Therapeutics Group Ltd.
North America was the dominant region in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-peptide small molecule glucagon-like peptide-1 (GLP-1) multi-indication pipeline market consists of sales of small-molecule metabolic disorder therapeutics, obesity management therapeutics, and non-alcoholic steatohepatitis therapeutics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market research report is one of a series of new reports that provides non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market statistics, including non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline industry global market size, regional shares, competitors with a non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market share, detailed non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market segments, market trends and opportunities, and any further data you may need to thrive in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline industry. This non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market size is expected to see exponential growth in the next few years. It will grow to $14.39 billion in 2030 at a compound annual growth rate (CAGR) of 31.4%. The growth in the forecast period can be attributed to the expansion of oral small molecule GLP-1 agonist development pipelines, widening applications of multi-indication metabolic therapies, rising innovation in non-peptide receptor modulation technologies, increasing strategic collaborations and licensing agreements among pharmaceutical and biotechnology companies, and a growing shift toward personalized approaches in metabolic disease management. Major trends in the forecast period include the expansion of oral non-peptide GLP-1 receptor agonist development, increasing growth of multi-indication metabolic therapeutics targeting obesity and diabetes, rising adoption of combination metabolic therapies for improved efficacy, advancements in small molecule drug discovery focused on GLP-1 pathway modulation, and development of next-generation oral bioavailability enhancement technologies for peptide-free metabolic drugs.
The rising prevalence of obesity is expected to drive the expansion of the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market in the future. Obesity is a medical condition characterized by excessive accumulation of body fat that can adversely affect health and increase the risk of diseases such as diabetes, cardiovascular disease, and hypertension. The increasing prevalence of obesity is primarily driven by unhealthy dietary patterns, including high consumption of calorie-dense, processed, and sugary foods, combined with low levels of physical activity. The non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline addresses obesity by enabling orally available GLP-1 receptor agonists that regulate appetite, enhance satiety, and improve metabolic function, thereby promoting sustained weight reduction. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, approximately 64.5% of adults aged 18 and over in England were classified as overweight or living with obesity, compared to 64% in 2022 to 2023. Therefore, the increasing prevalence of obesity is driving the growth of the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market.
Key companies operating in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market are focusing on conducting clinical trials to develop innovative products such as oral small-molecule GLP-1 receptor agonists to improve patient convenience, enhance metabolic disease management, and expand treatment options beyond injectable therapies. Oral small-molecule GLP-1 receptor agonists refer to chemically synthesized non-peptide compounds designed to mimic the activity of natural GLP-1 hormones by binding to and activating GLP-1 receptors, helping regulate blood glucose levels, suppress appetite, and support weight loss without requiring peptide-based injections. For example, in April 2026, Structure Therapeutics Inc., a US-based pharmaceutical company, announced that the first patients had been dosed in the Phase 2b ACCESS clinical study evaluating its oral small-molecule GLP-1 receptor agonist GSBR-1290 for the treatment of obesity. The study is designed to evaluate the safety, tolerability, and efficacy of the therapy in individuals with obesity, with a focus on its potential to support clinically meaningful weight reduction and improved metabolic outcomes. GSBR-1290 represents an oral, non-peptide alternative to injectable GLP-1 therapies, aiming to improve patient convenience and long-term treatment adherence.
In January 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical and diagnostics company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, F. Hoffmann-La Roche Ltd. aims to strengthen its obesity and diabetes pipeline by gaining access to Carmot Therapeutics Inc.’s portfolio of metabolic disease therapies, including CT-996, an oral non-peptide small-molecule GLP-1 receptor agonist, along with additional GLP-1 and GIP-targeting assets for obesity and type 2 diabetes treatment. Carmot Therapeutics Inc. is a US-based clinical-stage biotechnology company developing a non-peptide small-molecule GLP-1 receptor agonist-based pipeline for metabolic diseases.
Major companies operating in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market are Eli Lilly and Company, AstraZeneca PLC, Novo Nordisk A/S, Amgen, Viking Therapeutics Inc., Structure Therapeutics Inc., Metsera, Sciwind Biosciences Co. Ltd., Boehringer Ingelheim International GmbH, Roche Holding AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Zealand Pharma A/S, Hansoh Pharmaceutical Group Company Limited, Jiangsu Hengrui Pharmaceuticals Co Ltd., Septerna Inc., Eccogene Inc., Corxel Pharmaceuticals Limited, Gan And Lee Pharmaceuticals Co Ltd., Ascletis Pharma Inc., PegBio Co.Ltd., Regor Therapeutics Group Ltd.
North America was the dominant region in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-peptide small molecule glucagon-like peptide-1 (GLP-1) multi-indication pipeline market consists of sales of small-molecule metabolic disorder therapeutics, obesity management therapeutics, and non-alcoholic steatohepatitis therapeutics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market research report is one of a series of new reports that provides non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market statistics, including non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline industry global market size, regional shares, competitors with a non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market share, detailed non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market segments, market trends and opportunities, and any further data you may need to thrive in the non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline industry. This non-peptide small molecule glucagon-like peptide (GLP)-1 multi-indication pipeline market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Characteristics
3. Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Supply Chain Analysis
4. Global Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Trends And Strategies
5. Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Analysis Of End Use Industries
7. Global Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Total Addressable Market (TAM) Analysis for the Market
9. Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Segmentation
10. Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Regional And Country Analysis
11. Asia-Pacific Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
12. China Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
13. India Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
14. Japan Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
15. Australia Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
16. Indonesia Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
17. South Korea Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
18. Taiwan Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
19. South East Asia Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
20. Western Europe Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
21. UK Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
22. Germany Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
23. France Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
24. Italy Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
25. Spain Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
26. Eastern Europe Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
27. Russia Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
28. North America Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
29. USA Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
30. Canada Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
31. South America Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
32. Brazil Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
33. Middle East Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
34. Africa Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market
36. Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Competitive Landscape And Company Profiles
37. Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Other Major And Innovative Companies
41. Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses non-peptide small molecule glucagon-like peptide (glp)-1 multi-indication pipeline market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for non-peptide small molecule glucagon-like peptide (glp)-1 multi-indication pipeline? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-peptide small molecule glucagon-like peptide (glp)-1 multi-indication pipeline market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Class: Pure Glucagon Like Peptide One; Dual Agonists; Triple Agonists; Combination Therapies2) By Molecule Class: Non Peptide Small Molecule; Glucose Dependent Insulinotropic Polypeptide And Glucagon Like Peptide One Dual Agonist; Amylin Analog; Oral Peptide
3) By Route Of Administration: Oral; Injectable Comparator Or Reference; Other Delivery Formats
4) By Indication: Type Two Diabetes; Obstructive Sleep Apnea; Cardiovascular Disease; Osteoarthritis; Hypertension
5) By Development Stage: Phase One; Phase Two; Phase Three; Food And Drug Administration Approved
Subsegments:
1) By Pure Glucagon Like Peptide One: Oral Small Molecule Agonists; Injectable Peptide Analogues; Long Acting Formulations; Rapid Acting Formulations2) By Dual Agonists: Glucagon Like Peptide One And Glucose Dependent Insulinotropic Polypeptide Agonists; Glucagon Like Peptide One And Glucagon Receptor Agonists; Central And Peripheral Metabolic Dual Agonists; Oral Dual Receptor Agonists
3) By Triple Agonists: Glucagon Like Peptide One Glucose Dependent Insulinotropic Polypeptide And Glucagon Receptor Agonists; Multi Hormone Receptor Agonists; Metabolic Energy Balance Triple Agonists; Oral Triple Receptor Agonists
4) By Combination Therapies: Metformin Based Combinations; Sodium Glucose Cotransporter Two Inhibitor Combinations; Insulin Based Combinations; Dipeptidyl Peptidase Four Inhibitor Combinations
Companies Mentioned: Eli Lilly and Company; AstraZeneca PLC; Novo Nordisk A/S; Amgen; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Metsera; Sciwind Biosciences Co. Ltd.; Boehringer Ingelheim International GmbH; Roche Holding AG; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Zealand Pharma A/S; Hansoh Pharmaceutical Group Company Limited; Jiangsu Hengrui Pharmaceuticals Co Ltd.; Septerna Inc.; Eccogene Inc.; Corxel Pharmaceuticals Limited; Gan And Lee Pharmaceuticals Co Ltd.; Ascletis Pharma Inc.; PegBio Co.Ltd.; Regor Therapeutics Group Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Eli Lilly and Company
- AstraZeneca PLC
- Novo Nordisk A/S
- Amgen
- Viking Therapeutics Inc.
- Structure Therapeutics Inc.
- Metsera
- Sciwind Biosciences Co. Ltd.
- Boehringer Ingelheim International GmbH
- Roche Holding AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Zealand Pharma A/S
- Hansoh Pharmaceutical Group Company Limited
- Jiangsu Hengrui Pharmaceuticals Co Ltd.
- Septerna Inc.
- Eccogene Inc.
- Corxel Pharmaceuticals Limited
- Gan And Lee Pharmaceuticals Co Ltd.
- Ascletis Pharma Inc.
- PegBio Co.Ltd.
- Regor Therapeutics Group Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.82 Billion |
| Forecasted Market Value ( USD | $ 14.39 Billion |
| Compound Annual Growth Rate | 31.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
